21155 ⎘
Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum Stabilisation, fragmentation
Immunoglobulin polypeptide fractions from products of domestic animals
#602Aqueous composition comprising at least one protein and one solubilizing agent, preparation thereof and uses thereof
#603Anti-PD-1 antibodies and uses thereof
#604METHODS OF TREATING ULCERATIVE COLITIS
#605Liquid formulation comprising GM-CSF neutralizing compound
#606Immunoglobulin formulation and method of preparation thereof
#607Etanercept formulations stabilized with combinations of sugars and polyols
#608ANTIBODY FORMULATION
#609Anti-CD3 antibody formulations
#610ANTIBODY FORMULATION
#611Anti-CD40 antibody formulation
#612Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies
#613IMMUNOGLOBULIN PURIFICATION
#614Method of modifying isoelectric point of antibody via amino acid substitution in CDR
#615Stable aqueous formulations of adalimumab
#616Anti-CGRP antibody formulation
#617Etanercept formulations stabilized with metal ions
#618Method of monomerisation of recombinant antibody molecules
#619Anti-PD1 antibodies and their use as therapeutics and diagnostics
#620Pharmaceutical Formulations and Methods of Making the Same
#621Stable multi-dose compositions comprising an antibody and a preservative
#622STORAGE BUFFER
#623Room temperature stable lyophilized protein
#624Formulations for enteric delivery of therapeutic agents
#625METHOD OF REMOVING PROTEIN AGGREGATE
#626IL-17 antibody formulations and methods of treatment using same
#627ANTIBODY AND PROTEIN FORMULATIONS
#628Stable aqueous formulations of adalimumab
#629Stable aqueous formulations of adalimumab
#630Methods of Treatment by Administering an Anti-BAFFR Antibody Therapeutic Formulation
#631Stabilized formulations containing anti-PCSK9 antibodies
#632METHOD OF REDUCING IMMUNOGENICITY OF DRUG PRODUCTS
#633Stable aqueous formulations of adalimumab
#634Stable aqueous formulations of adalimumab
#635Purified antibody composition
#636ANTIBODY AND PROTEIN FORMULATIONS
#637Etanercept formulations stabilized with xylitol
#638Stable Aqueous Formulations of Adalimumab
#639Stable Aqueous Formulations of Adalimumab
#640Stable Aqueous Formulations of Adalimumab
#641Methods of manufacturing stable aqueous formulations of adalimumab
#642Syringe containing stable aqueous formulations of adalimumab
#643Pharmaceutical formulation comprising antibodies which bind colony stimulating factor-1 receptor (CSF1R)
#644Stable aqueous formulations of adalimumab
#645PHARMACEUTICAL FORMULATIONS FOR ANTI-TNF-ALPHA ANTIBODIES
#646Liquid formulation of long acting insulinotropic peptide conjugate
#647METHODS OF TREATING DISEASES
#648Use of PLL for improving the stability of molecules in solution
#649STABLE LIQUID FORMULATION FOR MONOCLONAL ANTIBODIES
#650Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
#651Stable antibody containing compositions
#652Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein
#653Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
#654FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES
#655Pharmaceutical formulation comprising anti-EGFR antibody
#656Pharmaceutical products and stable liquid compositions of IL-17 antibodies
#657SELF-BUFFERING PROTEIN FORMULATIONS
#658Method of manufacturing VEGF antagonist fusion proteins
#659STABLE AQUEOUS ANTIBODY FORMULATION FOR ANTI TNF ALPHA ANTIBODIES
#660CELL CULTURE METHODS TO REDUCE ACIDIC SPECIES
#661METHODS AND COMPOSITIONS FOR CONTROLLING ANTIBODY AGGREGATION
#662LOW ACIDIC SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME USING DISPLACEMENT CHROMATOGRAPHY
#663IMMUNOGLOBULINS WITH REDUCED AGGREGATION
#664STABLE MULTIVALENT ANTIBODY
#665Methods for reducing the viscosity of liquid pharmaceutical formulations comprising therapeutic proteins
#666Stabilized radiolabeled anti-CD45 immunoglobulin compositions
#667PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES
#668Stable aqueous formulations of adalimumab
#669Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies
#670METHODS FOR MODULATING THE GLYCOSYLATION PROFILE OF RECOMBINANT PROTEINS USING DISSOLVED OXYGEN
#671Method of filling a container with no headspace
#672Carrier-binding agent compositions and methods of making and using the same
#673HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY
#674STABLE ANTI-IL-4Ra FORMULATION
#675NOVEL NUCLEIC ACID MOLECULES WITH ANTITUMORAL ACTIVITY
#676Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus
#677Combination Therapy For Treatment of Cancer
#678Anti-PD-L1 antibodies and uses thereof
#679Anti-PD-L1 antibodies and uses thereof
#680PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION
#681Liquid formulation comprising GM-CSF neutralizing compound
#682Methods of preventing and removing trisulfide bonds
#683ANTI-IL-7R ANTIBODY COMPOSITIONS
#684Anti-PDGF-B antibodies and methods of use
#685FORMULATIONS OF ANTIBODY MOLECULES TO INFLUENZA VIRUS
#686Pre-Filled Plastic Syringe Containing a VEGF Antagonist
#687Stable IGG4 based binding agent formulations
#688Excipient compounds for biopolymer formulations
#689COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS
#690Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#691Anti-epidermal growth factor receptor (EGFR) antibodies
#692Stable Dual Variable Domain Immunoglobulin Protein Formulations
#693Antibody formulations
#694PROTEIN FORMULATIONS
#695Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
#696Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
#697Stabilization of Aqueous Compositions of Proteins With Displacement Buffers
#698CRYSTALLINE ANTIBODY FORMULATIONS
#699Crystalline antibody formulations
#700Liquid pharmaceutical composition
#701Carrier immunoglobulins
#702Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
#703Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
#704Formulations with reduced degradation of polysorbate
#705STABLE AQUEOUS ADALIMUMAB FORMULATION
#706Adalimumab formulations
#707NANOENCAPSULATION OF ANTIGEN-BINDING MOLECULES
#708Liquid pharmaceutical composition
#709Stabilized angiopoietin-2 antibodies and uses thereof
#710Humanized antibodies with increased stability
#711Formulation of human antibodies for treating TNF-alpha associated disorders
#712LOW ACIDIC SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME
#713Formulation of human antibodies for treating TNF-alpha associated disorders
#714Kits comprising formulations of anti-C5 antibodies
#715Anti-factor D antibodies and conjugates
#716Formulation of human antibodies for treating TNF-alpha associated disorders
#717Serum half-life extension using IgBD
#718PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
#719Compositions comprising a combination of nivolumab and ipilimumab
#720PURIFIED ANTIBODY COMPOSITION
#721Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
#722Methods and apparatus for false positive minimization in facial recognition applications
#723Stable protein-containing preparation containing argininamide or analogous compound thereof
#724Method for preparing antibody through regulation of sugar content of antibody
#725TNF alpha antibody or fragment thereof and methods of use
#726Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
#727Liquid pharmaceutical composition of adalimumab
#728Anti-Blys antibody formulations and methods of treatment using them
#729Feeding strategies and purification processes for monoclonal antibody production
#730METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
#731Stable aqueous formulations of adalimumab
#732Anti-IL-17A Antibodies
#733Antibody preparations
#734Formulation of human antibodies for treating TNF-alpha associated disorders
#735Stable anti-IFNAR1 formulation
#736HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS
#737Bioerodible silicon-based compositions for delivery of therapeutic agents
#738Stable protein formulations comprising a molar excess of sorbitol
#739STABLE FORMULATIONS FOR ANTI-CD19 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#740Nebultzation of immunoglobulin
#741Immunoglobulin preparation and storage system for an immunoglobulin preparation
#742ANTI-PROLACTIN RECEPTOR ANTIBODY FORMULATIONS
#743Methods of treating ulcerative colitis
#744METHODS FOR PRODUCING HIGH CONCENTRATION LYOPHILIZED PHARMACEUTICAL FORMULATIONS
#745ANTIBODY FORMULATION
#746Human CD3 binding antibody
#747SELF-BUFFERING PROTEIN FORMULATIONS
#748SELF-BUFFERING PROTEIN FORMULATIONS
#749Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
#750Protein sustained-release injectable formulation
#751Formulation for anti-α4β7 antibody
#752Methods of treating ulcerative colitis
#753Stable protein solution formulation containing high concentration of an anti-VEGF antibody
#754SELF-BUFFERING PROTEIN FORMULATIONS
#755Method for purifying antibody having low isoelectric point
#756Anti-PDL1 antibody formulations
#757SELF-BUFFERING PROTEIN FORMULATIONS
#758Etanercept formulations stabilized with xylitol
#759Antibody formulations and methods for treating AL amyloidosis
#760Stable aqueous formulations of adalimumab
#761Stable aqueous formulations of adalimumab
#762Stable aqueous formulations of adalimumab
#763Stable aqueous formulations of adalimumab
#764Stable aqueous formulations of adalimumab
#765Stable aqueous formulations of adalimumab
#766Human anti-IL-33 neutralizing monoclonal antibody
#767IL-17 antibody formulations and methods of treatment using same
#768STABLE FORMULATIONS OF POLYPEPTIDES AND USES THEREOF
#769Methods for treating atypical hemolytic uremic syndrome with high concentration formulations of anti-C5 antibodies
#770Protein Formulations Containing Amino Acids
#771Antibodies for treatment of cancer expressing claudin 6
#772Stable aqueous formulations of adalimumab
#773Formulations of single domain antigen binding molecules
#774Stable aqueous formulations of adalimumab
#775Stable aqueous formulations of adalimumab
#776Stable aqueous formulations of adalimumab
#777Protein purification methods to reduce acidic species
#778ANTIBODY COMPOSITION
#779Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
#780VEGF specific fusion protein antagonist formulations
#781Binding molecules specific for HER3 and uses thereof
#782High concentration antibody formulations
#783Buffer formulations for enhanced antibody stability
#784Methods for treating patients with complement-associated disorders with high concentration formulations of anti-C5 antibodies
#785Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide
#786Protein drug formulations and packages
#787Compositions and methods for stabilizing protein-containing formulations
#788Etanercept formulations stabilized with combinations of sugars and polyols
#789Stable VEGF antagonist formulations
#790Pharmaceutical compositions containing sc(Fv)2
#791Subcutaneous anti-HER2 antibody formulations and uses thereof
#792Stabilized antibody compositions
#793Stabilized liquid anti-RSV antibody formulations
#794METHODS AND FORMULATIONS WHICH ALLOW THE MODULATION OF IMMUNE RESPONSES RELATED TO THE ADMINISTRATION OF A BIOPHARMACEUTICAL DRUG
#795Methods of treatment by administering an anti-BAFFR antibody therapeutic formulation
#796Cell culture methods to reduce acidic species
#797Glycan-interacting compounds and methods of use
#798Pharmaceutical Compositions Comprising Pyrophosphate
#799Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
#800Composition for stabilizing protein and pharmaceutical formulation comprising the same
#801Methods of controlling the formation of disulfide bonds in protein solutions
#802Process for reducing subvisible particles in a pharmaceutical formulation
#803Viscosity-reducing excipient compounds for protein formulations
#804Stable formulations of immunoglobulin single variable domains
#805HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION
#806Sclerostin antibody crystals and formulations thereof
#807Wnt antagonist and methods of treatment and screening
#808Anti-IL-4/anti-IL-13 bispecific antibody formulations
#809VISCOSITY-REDUCING EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS
#810LOW VISCOSITY CONCENTRATED PROTEIN DISPERSIONS
#811Stable aqueous formulations of adalimumab
#812Cell culture methods to reduce acidic species
#813Stable aqueous formulations of adalimumab
#814Formulation of human antibodies for treating TNF-α associated disorders
#815CONCENTRATED HUMAN IMMUNOGLOBULIN COMPOSITION
#816Methods for the treatment of autoimmune diseases
#817Anti-factor D antibodies
#818Anti-VLA1 (CD49A) antibody pharmaceutical compositions
#819Anti-interleukin-13 antibody compositions
#820Low concentration antibody formulations
#821Polyclonal antibodies against and uses thereof
#822Formulation of human antibodies for treating TNF-alpha associated disorders
#823Formulation of human antibodies for treating TNF-alpha associated disorders
#824Formulation of human antibodies for treating TNF-alpha associated disorders
#825Formulation of human antibodies for treating TNF-alpha associated disorders
#826Formulation of human antibodies for treating TNF-alpha associated disorders
#827ANTIBODY FORMULATION
#828Methods of producing immunoconjugates
#829Pharmaceutical formulations
#830Formulation for bispecific T-cell engagers (BiTEs)
#831Liquid formulations for an anti-TNF α antibody
#832Saposin-A derived peptides and uses thereof
#833Anti-PD1 antibodies and their use as therapeutics and diagnostics
#834Liquid formulation comprising GM-CSF neutralizing compound
#835Formulation of human antibodies for treating TNF-alpha associated disorders
#836Stabilized antibody-containing formulations
#837Method of modifying isoelectric point of antibody via amino acid substitution in CDR
#838HER2- and VEGF-A-binding proteins with enhanced stability
#839Human domain antibodies against components of the human insulin-like growth factor (IGF) system
#840Stable, Low Viscosity Antibody Formulation
#841High concentration antibody and protein formulations
#842Immunoglobulin reduced in thrombogenic agents and preparation thereof
#843Stable aqueous formulations of adalimumab
#844Stable aqueous formulations of adalimumab
#845Stable aqueous formulations of adalimumab
#846Stable aqueous formulations of adalimumab
#847Method of stabilizing antibody and stabilized solution-type antibody preparation
#848Stable aqueous formulations of adalimumab
#849Low acidic species compositions and methods for producing and using the same using displacement chromatography
#850Crystalline anti-human IL-23p19 antibodies
#851Protein purification methods to reduce acidic species
#852Stabilized human IgG4 antibodies
#853Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
#854Variant immunoglobulins with improved manufacturability
#855Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
#856Formulation of human antibodies for treating TNF-α associated disorders
#857Stabilised protein solutions
#858Stabilized liquid anti-RSV antibody formulations
#859Anti-PD1 antibodies and their use as therapeutics and diagnostics
#860Antibody formulations and methods
#861Pharmaceutical formulations of TNF-alpha antibodies
#862Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
#863HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING
#864Anti-c-met-antibody formulations
#865Antibody preparations
#866Binding molecules with antitumoral activity
#867Carrier immunoglobulins
#868Carrier immunoglobulins
#869Protein sustained-release injectable formulation
#870Reduced-viscosity concentrated protein formulations
#871Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
#872High concentration antibody and protein formulations
#873Anti-TNF antibody formulations
#874Method of treating psoriasis using an IL-17 receptor antibody formulation
#875IL-17 antibody formulation and method of treatment using same
#876Stabilized aqueous antibody compositions
#877Formulation for anti-α4β7 antibody
#878Process for concentration of antibodies and therapeutic products thereof
#879Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
#880Antibody formulations
#881Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
#882Immunoglobulins with reduced aggregation
#883Stabilized formulations containing anti-PCSK9 antibodies
#884Formulation of human antibodies for treating TNF-α associated disorders
#885Anti-PD-L1 antibodies and uses thereof
#886Formulation for anti-α4β7 antibody
#887Compositions for cell culture and methods of using the same
#888Formulation of human antibodies for treating TNF-alpha associated disorders
#889Formulations with reduced oxidation
#890Formulation of human antibodies for treating TNF-α associated disorders
#891FORMULATIONS WITH REDUCED OXIDATION
#892Antibody formulations
#893Liquid formulation containing a protein drug
#894Complement antagonists and uses thereof
#895Methods of preventing and removing trisulfide bonds
#896Methods of preparing lyophilized spherical-shaped pellets of biological materials
#897Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
#898Anti-prolactin receptor antibody formulations
#899Immuno imaging agent for use with antibody-drug conjugate therapy
#900Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments